Not medical advice. This is educational reading about NAD+ and the supplements and IV drips built around it. It's not a recommendation to start, stop, or change anything. Talk to your own doctor before you try anything, especially if you take medicine or you're managing a health condition.
What it is
Pull up a chair. NAD+ isn't technically a peptide, but it's been sitting on the same porch for a while, so it gets a turn.
NAD+ (short for nicotinamide adenine dinucleotide... say that three times fast) is a helper molecule that every cell in your body uses. Think of it like the spark plug wires on an old truck. It helps turn food into energy, and a whole crew of maintenance enzymes run on it too, including the ones that help repair DNA and the "sirtuins" you've probably seen in longevity headlines.
Your body builds NAD+ from forms of vitamin B3 in food and recycles it all day long.
I haven't tried NAD+ myself, but it keeps popping up every time folks talk about healthy aging, so I figured it was time to pull up a chair and see what the research actually says.
Why levels drop with age
In mice and other lab animals, NAD+ drifts down with age in a lot of tissues, and topping it back up has helped with several age-related problems. That's where all the excitement started.
People show it too, at least in some places. A study of human skin samples found lower NAD+ in older folks, and a blood study of healthy adults ages 20 to 87 found plasma NAD+ went down with age. The leading idea is that as we get older, more DNA wear and tear and more inflammation keep those repair crews busy, and they burn through NAD+ faster than we make it.
Honest note: the human picture is a lot thinner than the mouse picture, and it may not look the same in every tissue. In fact, two big 2026 studies in Nature Metabolism, covering well over a thousand adults, found that NAD+ in whole blood held steady with healthy aging. One found it ran lower in people with heart disease and high blood pressure instead. So "everybody runs low as they age" may be too simple.
The ways people try to raise it
Precursors (NR and NMN). Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are vitamin B3 relatives your body can turn into NAD+. They're sold as pills and powders, and they're the ones with the most human research.
IV drips and shots. Some clinics offer NAD+ itself by IV or injection. The idea is to skip the gut and go straight to the bloodstream. It's popular, but it has much less careful study behind it than the pills. More on that below.
What people like / are saying
NAD+ comes up a lot on the porch and online. Treat these as personal reports, not proof.
More get-up-and-go. The most common story is steadier energy and less of that afternoon slump.
Clearer head. Some folks describe less brain fog and better focus.
Bouncing back. Gym folks and weekend yard warriors say they recover a little quicker.
The honest shrug. Plenty of people take it for months and can't tell a lick of difference. Fair enough.
Hope is real. Placebo is real. Neither one replaces a careful study.
What the research shows
Good news first. The pills do one important thing they promise: they raise NAD+ in people.
It gets in. The first human study of NR (Trammell et al., 2016) found single doses raised NAD+ markers in the blood, more with bigger doses. NMN trials in healthy middle-aged adults (Yi et al., 2023) and healthy older men (Igarashi et al., 2022) raised blood NAD+ too. And a small study of 12 older men (Elhassan et al., 2019) found NR made it all the way to muscle.
It's been well tolerated so far. In trials lasting weeks to a few months, NR and NMN have generally been safe and well tolerated, and a 2023 review of the human studies came to the same conclusion. Even a year-long NR trial in about 400 people with early Parkinson's didn't turn up more serious side effects than placebo.
Some promising signals.
Blood pressure. In a small crossover trial of healthy middle-aged and older adults (Martens et al., 2018), NR raised NAD+ and the researchers saw hints worth chasing on blood pressure and artery stiffness. A hint, not proof, and they said bigger trials are needed.
Blood sugar. A 10-week trial in Science (Yoshino et al., 2021) gave NMN or placebo to postmenopausal women with prediabetes and extra weight. Muscle insulin sensitivity improved with NMN and not with placebo.
Walking. In a 60-day trial of 80 healthy middle-aged adults (Yi et al., 2023, company-funded), the NMN groups walked farther on a six-minute walk test than the placebo group. The older-men study (Igarashi et al., 2022) saw small improvements in walking speed and grip that the authors said need bigger studies to confirm.
Inflammation. In the 12-man muscle study, NR lowered some inflammation markers in the blood.
And a few flat tires. This is the part the ads leave out.
In 40 men with obesity, 12 weeks of NR didn't improve insulin sensitivity or body composition (Dollerup et al., 2018).
A 2025 review that pooled the trials in adults over 60 concluded the current evidence doesn't support NR or NMN for holding onto muscle mass and strength (Prokopidis et al., 2025).
The big one: a year-long trial of NR in about 400 people with early Parkinson's, published in JAMA in October 2026 (the NOPARK trial), found it didn't help, and symptom scores came out a little worse than placebo. That's a specific disease, not healthy aging, but it's a good reminder that a great mouse story doesn't always hold up in people.
IV and shots. A 2026 review of IV "longevity" drips, NAD+ included, found mostly small studies, very few placebo-controlled trials, results that don't agree with each other, and real procedural risks. The authors called it experimental. A handful of small placebo-controlled trials have tested short courses of IV NAD+ in hospital heart patients, with modest results. But a 2026 systematic review found no outcome trials of NAD+ drips or shots for anti-aging or wellness, and the first placebo-controlled trial aimed at aging hasn't started enrolling yet.
Bottom line. NR and NMN reliably raise NAD+ in people and look safe in short trials. The payoff so far is mixed: some encouraging signals in small studies, some clear misses, and no human proof yet that any of it slows aging. Curiosity welcome. Hype optional.
Open questions / who should be careful
Does raising NAD+ in the blood mean it rises where it counts, like muscle and brain? Do only people who start out low get a benefit? Is NR better than NMN, or the other way around? What happens over years instead of months? Researchers writing in Nature Reviews say a lot of NAD+ biology is still poorly understood, and that includes the possible risks of boosting it.
Please talk to your doctor first if any of this is you:
You take prescription medicine, especially for blood sugar or blood pressure
You have cancer or a history of it. Cancer cells use NAD+ to grow too, and in one mouse study NR helped an aggressive breast cancer spread. Other lab studies point the other way, and there's no human evidence of harm, but it's worth a conversation first.
You have Parkinson's disease (the big year-long NR trial came out slightly worse than placebo)
You have kidney, liver, or heart disease, or another serious condition your clinician is managing
You're pregnant, trying, or breastfeeding, or you're asking on behalf of someone under 18
You're thinking about IV drips or shots. Ask who's giving it, what's in the bag, and whether a licensed clinician is involved. Nausea, cramping, flushing, and chest tightness are common during NAD+ infusions, so mention any heart history.
One more thing about the pill aisle. The FDA doesn't approve dietary supplements before they're sold, so it's on the maker to get it right. Your doctor or pharmacist can help you check for interactions.
Your turn: what should we chew on next? Tap one below and I'll dig into the winner :-)
What should we break down next on the porch?
Got an NAD+ story, good or bad? Just hit reply. I'd love to hear what folks on the porch have found.
Catch me on YouTube too: Old Hat, New Tricks
And on X: @MikeLeturno
Curiosity welcome. Hype optional. Roll Tide. 🐘
Sources
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021. https://pubmed.ncbi.nlm.nih.gov/33353981/
Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012. https://pubmed.ncbi.nlm.nih.gov/22848760/
Clement J, et al. The plasma NAD+ metabolome is dysregulated in "normal" aging. Rejuvenation Res. 2019. https://pubmed.ncbi.nlm.nih.gov/30124109/
Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016. https://pubmed.ncbi.nlm.nih.gov/27721479/
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018. https://pubmed.ncbi.nlm.nih.gov/29599478/
Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019. https://pubmed.ncbi.nlm.nih.gov/31412242/
Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018. https://pubmed.ncbi.nlm.nih.gov/29992272/
Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. https://pubmed.ncbi.nlm.nih.gov/33888596/
Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. https://pubmed.ncbi.nlm.nih.gov/36482258/
Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. NPJ Aging. 2022. https://pubmed.ncbi.nlm.nih.gov/35927255/
Freeberg KA, et al. Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions. J Gerontol A Biol Sci Med Sci. 2023. https://pubmed.ncbi.nlm.nih.gov/37068054/
Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025. https://pubmed.ncbi.nlm.nih.gov/40275690/
Brakedal B, et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA. 2026. https://pubmed.ncbi.nlm.nih.gov/42848371/
Godic A, Townsend J. Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility. Acta Dermatovenerol Alp Pannonica Adriat. 2026. https://pubmed.ncbi.nlm.nih.gov/41915584/
Migaud ME, et al. Regulation of and challenges in targeting NAD+ metabolism. Nat Rev Mol Cell Biol. 2024. https://pubmed.ncbi.nlm.nih.gov/39026037/
U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
Trętowicz MM, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026. https://pubmed.ncbi.nlm.nih.gov/42135539/
Romenskaja-Avgul D, et al. Whole-blood NAD levels track cardiovascular disease but not chronological age. Nat Metab. 2026. https://www.nature.com/articles/s42255-026-01660-3
Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026. https://pubmed.ncbi.nlm.nih.gov/41655607/
Yu X, et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2026. https://pubmed.ncbi.nlm.nih.gov/40954388/
ClinicalTrials.gov NCT07328100. IV NAD+ for vascular aging (not yet recruiting). https://clinicaltrials.gov/study/NCT07328100
Maric T, et al. A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism. Biosens Bioelectron. 2023. https://pubmed.ncbi.nlm.nih.gov/36371959/
Navas LE, Carnero A. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021. https://pubmed.ncbi.nlm.nih.gov/33384409/
Alangari A, et al. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging. 2026. https://pubmed.ncbi.nlm.nih.gov/42787547/
Reyna K, et al. Intravenous infusion of NAD+ versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026. https://pubmed.ncbi.nlm.nih.gov/41704678/

